Suppr超能文献

肾小管转运体与阿德福韦的清除率

Tubular transporters and clearance of adefovir.

作者信息

Servais Aude, Lechat Philippe, Zahr Noël, Urien Saik, Aymard Guy, Jaudon Marie Chantal, Deray Gilbert, Isnard Bagnis Corinne

机构信息

Nephrology Department, Pitié-Salpêtrière University Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France.

出版信息

Eur J Pharmacol. 2006 Jul 1;540(1-3):168-74. doi: 10.1016/j.ejphar.2006.04.047. Epub 2006 May 6.

Abstract

Adefovir is transported by the organic anion transporter (OAT1) and the multidrug resistant protein (MRP2, 4 and 5). We studied adefovir clearance in rat after inhibition of transporters by probenecid and in mutant transport-deficient (TR-) rats, in which MRP2 is lacking. After treatment by probenecid or placebo, pharmacokinetics of adefovir 10mg/kg was studied via population nonlinear mixed effect modeling. The fraction of drug excreted in the urine was low. Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03+/-0.02l/h) than in normal control (0.09+/-0.05l/h), in normal probenecid (0.10+/-0.07l/h) and in TR- control rats (0.13+/-0.07l/h). In vivo in rats MRP2 mutation alone did not affect adefovir clearance suggesting that MRP2 does not play a critical role in the secretion of adefovir. Additional pharmacological inhibition of transporters decreased renal clearance, which may reflect inhibition of compensating transport mechanisms activated when MRP2 is lacking.

摘要

阿德福韦通过有机阴离子转运体(OAT1)以及多药耐药蛋白(MRP2、MRP4和MRP5)进行转运。我们研究了丙磺舒抑制转运体后大鼠体内阿德福韦的清除情况,以及在缺乏MRP2的转运缺陷(TR-)突变大鼠中的清除情况。在丙磺舒或安慰剂处理后,通过群体非线性混合效应模型研究了10mg/kg阿德福韦的药代动力学。经尿液排泄的药物比例较低。丙磺舒处理的TR-大鼠(0.03±0.02l/h)中阿德福韦的肾清除率显著低于正常对照(0.09±0.05l/h)、正常丙磺舒处理组(0.10±0.07l/h)以及TR-对照大鼠(0.13±0.07l/h)(P<0.05)。在大鼠体内,单独的MRP2突变并不影响阿德福韦的清除率,这表明MRP2在阿德福韦的分泌过程中不发挥关键作用。对转运体的额外药理抑制降低了肾清除率,这可能反映出当缺乏MRP2时激活的代偿性转运机制受到了抑制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验